CA
NAVB

CoreCap Advisors’s Navidea Biopharmaceuticals Inc. NAVB Stock Holding History

CoreCap Advisors’s Portfolio NAVB Stock Details NAVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-45
Closed – – 2347
2022
Q2 		$0 Buy
+45
New +$38 ﹤0.01% 2360
2022
Q1 		– Sell
-45
Closed -$1K – 2359
2021
Q4 		$1K Buy
+45
New +$63 ﹤0.01% 2372

Other funds holding NAVB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ACM
Allred Capital Management Dallas, Texas $275M AUM 18.19% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

CoreCap Advisors's NAVB Position: Q3 2022 in Review

CoreCap Advisors sold out of Navidea Biopharmaceuticals Inc. (NAVB) in Q3 2022, closing a stake of 45 shares.

CoreCap Advisors first reported a position in NAVB in Q4 2021 and held it in 2 quarters. The position peaked at $1K in Q4 2021. 25 funds tracked by Wall St. Rank hold NAVB as of Q3 2022.

  • CoreCap Advisors reported no remaining Navidea Biopharmaceuticals Inc. position as of Q3 2022 after selling out during the quarter.
  • CoreCap Advisors sold 45 Navidea Biopharmaceuticals Inc. shares in Q3 2022.
  • CoreCap Advisors first reported a position in Navidea Biopharmaceuticals Inc. in Q4 2021 and held it in 2 quarters.
  • CoreCap Advisors's Navidea Biopharmaceuticals Inc. position peaked at $1K in Q4 2021.
  • 25 funds tracked by Wall St. Rank held Navidea Biopharmaceuticals Inc. as of Q3 2022.

Based on CoreCap Advisors's 13F filing for Q3 2022, filed 10 Feb 2023.